Two 2026 interim injunction orders from the Madras High Court IP Division demonstrate heightened judicial scrutiny over alpha-numeric pharmaceutical trademarks. In Nouveau Medicament Private Limited v. Foregen Healthcare Ltd. (7 January 2026, C.S. (Comm. Div.) No. 184 of 2025), Justice Senthilkumar Ramamoorthy restrained the mark 'URG-9' as deceptively similar to the Chennai-based plaintiff's registered mark 'ARG-9'.
Later, on 27 July 2026, Justice K. Kumaresh Babu granted a similar ad-interim injunction in Nouveau Medicament Private Limited v. Orange Biotech Private Limited & Ors., restraining three pharmaceutical companies from manufacturing or selling products under 'ORG-9'.
In both matters, the Court noted that altering a single vowel or letter arrangement around the same numeral ('-9') in overlapping medicinal products creates a high risk of phonetic confusion among doctors, chemists, and patients—where even minor confusion carries serious public-health consequences.
Healthcare, nutraceutical, and D2C wellness brands should avoid coined alpha-numeric names that closely echo existing registered marks. Shadow Business Solutions conducts thorough phonetic clearance searches and brand-watch monitoring.
Talk to our team about your business requirements.